Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome

被引:77
作者
Krishna, Gopal [1 ]
AbuTarif, Malaz [1 ]
Xuan, Fengjuan [1 ]
Martinho, Monika [1 ]
Angulo, David [1 ]
Cornely, Oliver A. [2 ,3 ]
机构
[1] Schering Plough Corp, Res Inst, Kenilworth, NJ 07033 USA
[2] Klinikum Univ Koeln, Dept Internal Med 1, Cologne, Germany
[3] Klinikum Univ Koeln, Ctr Clin Trials, Cologne, Germany
来源
PHARMACOTHERAPY | 2008年 / 28卷 / 10期
关键词
azole; neutropenia; prophylaxis; acute myelogenous leukemia; AML; myelodysplastic syndrome; MDS; pharmacokinetics; posaconazole;
D O I
10.1592/phco.28.10.1223
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Study Objective. To analyze the pharmacokinetics of posaconazole administered as prophylaxis for invasive fungal infection (IFI) in neutropenic patients receiving chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS). Design. Pharmacokinetic subanalysis of a phase III, prospective, randomized, multicenter, evaluator-blinded trial comparing posaconazole with standard azoles (fluconazole and itraconazole). Patients. One hundred ninety-four patients with AML or MDS who received posaconazole oral suspension 200 mg 3 limes/day with meals or a nutritional supplement for a minimum of 7 days to achieve steady state and for a maximum of 12 weeks. Intervention. For the first 20 patients, blood samples were collected before the first dose on day 8 and at 2, 4, 6, and 24 hours after that first dose; for all other patients, blood samples were collected at 1. and 3 hours after the first dose on day 8 and during the first episode of evaluation for a possible IFI. Measurements and Main Results. The effects of the following covariates on average (C-av) and maximum (C-max) posaconazole plasma concentrations at steady state were explored: age, sex, and race-ethnicity; proven or probable IFI; baseline body weight and body surface area; and baseline (on or before day 7) increases in liver enzyme levels, mucositis, neutropenia, diarrhea, vomiting, or use of an H-2-receptor antagonist or proton pump inhibitor. Diarrhea, proton pump inhibitor use, gamma-glutamyl transferase level of 2 or more times the upper limit of normal, and race-ethnicity reduced C-av. Although statistically significant, these results were not considered clinically significant and did not necessitate posaconazole dosage adjustments. Mean C-av and C-max values did not appear different in the six patients with IFIs (three with proven IFIs, three with probable IFIs) compared with the entire sample of 194 patients; however, a definitive conclusion cannot be made due to the small sample size of patients with IFI. No factor found to affect posaconazole concentrations predominated in patients with IFIs. Conclusion. Oral posaconazole 200 mg 3 times/day provided plasma concentrations adequate for preventing IFIs. No dosage adjustments are recommended based on any covariate tested.
引用
收藏
页码:1223 / 1232
页数:10
相关论文
共 39 条
[1]   Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus [J].
Ascioglu, S ;
Rex, JH ;
de Pauw, B ;
Bennett, JE ;
Bille, J ;
Crokaert, F ;
Denning, DW ;
Donnelly, JP ;
Edwards, JE ;
Erjavec, Z ;
Fiere, D ;
Lortholary, O ;
Maertens, J ;
Meis, JF ;
Patterson, TF ;
Ritter, J ;
Selleslag, D ;
Shah, PM ;
Stevens, DA ;
Walsh, TJ .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (01) :7-14
[2]   ANTIFUNGAL PROPHYLAXIS WITH ITRACONAZOLE IN PROLONGED NEUTROPENIA - CORRELATION WITH PLASMA-LEVELS [J].
BOOGAERTS, MA ;
VERHOEF, GE ;
ZACHEE, P ;
DEMUYNCK, H ;
VERBIST, L ;
DEBEULE, K .
MYCOSES, 1989, 32 :103-108
[3]   INVASIVE FUNGAL DISEASE IN ADULTS UNDERGOING REMISSION-INDUCTION THERAPY FOR ACUTE MYELOID-LEUKEMIA - THE PATHOGENETIC ROLE OF THE ANTILEUKEMIC REGIMEN [J].
BOW, EJ ;
LOEWEN, R ;
CHEANG, MS ;
SCHACTER, B .
CLINICAL INFECTIOUS DISEASES, 1995, 21 (02) :361-369
[4]   Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia [J].
Cornely, Oliver A. ;
Maertens, Johan ;
Winston, Drew J. ;
Perfect, John ;
Ullmann, Andrew J. ;
Walsh, Thomas J. ;
Helfgott, David ;
Holowiecki, Jerzy ;
Stockelberg, Dick ;
Goh, Yeow-Tee ;
Petrini, Mario ;
Hardalo, Cathy ;
Suresh, Ramachandran ;
Angulo-Gonzalez, David .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (04) :348-359
[5]   Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease [J].
Courtney, R ;
Sansone, A ;
Smith, W ;
Marbury, T ;
Statkevich, R ;
Martinho, M ;
Laughlin, M ;
Swan, S .
JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (02) :185-192
[6]   Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men [J].
Courtney, R ;
Radwanski, E ;
Lim, J ;
Laughlin, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (03) :804-808
[7]   Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults [J].
Courtney, R ;
Wexler, D ;
Radwanski, E ;
Lim, J ;
Laughlin, M .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 57 (02) :218-222
[8]   Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults [J].
Courtney, R ;
Pai, S ;
Laughlin, M ;
Lim, J ;
Batra, V .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (09) :2788-2795
[9]  
COURTNEY R, 2003, 13 EUR C CLIN MICR I
[10]   Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis [J].
Denning, DW ;
Ribaud, P ;
Milpied, N ;
Caillot, D ;
Herbrecht, R ;
Thiel, E ;
Haas, A ;
Ruhnke, M ;
Lode, H .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (05) :563-571